Meta-analysis of the effects of monensin in beef cattle on feed efficiency, body weight gain, and dry matter intake.

A meta-analysis of the impact of monensin on growing and finishing beef cattle was conducted after a search of the literature. A total of 40 peer-reviewed articles and 24 additional trial reports with monensin feeding in beef cattle were selected, after meeting apriori quality criteria. Data for each trial were extracted and analyzed using meta-analysis software in STATA. Estimated effect size of monensin was calculated for feed efficiency (FE), ADG, and DMI. Monensin use in growing and finishing beef cattle reduced DMI (P < 0.001) and improved both ADG (P < 0.001) and FE (P < 0.001). The average concentration of monensin in feed across studies was 28.1 mg/kg feed (100% DM) and this resulted in approximately a 6.4% (but only 2.5 to 3.5% in the last 2 decades) increase in FE, 3% decrease in DMI, and 2.5% increase in ADG. All 3 outcomes displayed moderate and significant heterogeneity of monensin response (I(2), which is a measure of variation beyond chance, = 29% for FE, 42% for DMI, and 23% for ADG); therefore, random effects models were used for those outcomes. There were no single influential studies that overweighted the findings for any outcome. Meta-regression analysis of the effect sizes obtained from these data showed that dietary factors, dose, and study design were influential in modifying effect size of monensin treatment. Use of corn silage in the diet influenced the effect size of monensin for DMI and FE, with diets containing corn silage resulting in a greater improvement in FE and a larger effect on reducing DMI. Studies conducted to assess multiple doses of monensin showed similar effects to the use of corn silage in the diet. Studies conducted in the United States or with higher ADG in control animals (>1.17 kg/d) showed less effect of monensin on ADG. Pen-level studies showed a greater monensin increase on ADG than did those conducted on individual animals. Linear effect of monensin dose was observed for FE, DMI, and ADG outcomes, with greater effects on improving FE and reducing DMI with larger doses of monensin but lesser improvement in ADG with increasing dose. These findings confirm that monensin improves FE in growing and finishing beef cattle, and that this effect is linear with dose.

A randomized herd-level field study of dietary interactions with monensin on milk fat percentage in dairy cows.

This field trial evaluated the effects of dietary supplementation with 16 mg/kg (based on total dry matter intake) of monensin sodium on bulk tank milk fat percentage (MFP) of commercial dairy herds. Interactions between monensin and nutritional factors on MFP were studied. The trial was conducted in 47 Holstein dairy herds in Québec, Canada, between November 2005 and May 2006. The herd was the unit of interest. Enrolled herds were followed for a 7-mo period. Monensin treatment was randomly allocated in a crossover design where monensin was supplemented to the lactating dairy cow diet for a consecutive 12-wk period. Twenty-four herds were allocated to monensin treatment for the first period of trial, and 23 herds were allocated for the second period. Diet composition and ration physically effective particle level were collected every 8 wk. Milk fat percentage data were retrieved from weekly bulk tank measures. Data were analyzed in linear mixed models using repeated measures within herd where MFP was considered the outcome variable. In addition to the main effect of monensin treatment, the following covariates were forced a priori into all statistical models: treatment period, weekly herd mean parity, and weekly herd mean days in milk. The majority of herds were fed a total mixed ration (n = 29) and were housed in tie-stalls (n = 42). Monensin significantly decreased bulk tank MFP by 0.12 percentage points. The reduction of MFP associated with monensin was larger for herds having a diet high (>39.7%) in nonfiber carbohydrates, having a low level of physically effective particles in ration (>45.0%; >or=8 mm), and not feeding dry hay as first meal in the morning. Significant interactions between monensin and nutritional factors on bulk tank MFP were related to nonfiber carbohydrate and fiber concentrations in the diet.

Effects of monensin and dietary soybean oil on milk fat percentage and milk fatty acid profile in lactating dairy cows.

The objective of this study was to investigate the effect of monensin (MN) and dietary soybean oil (SBO) on milk fat percentage and milk fatty acid (FA) profile. The study was conducted as a randomized complete block design with a 2 x 3 factorial treatment arrangement using 72 lactating multiparous Holstein dairy cows (138 +/- 24 d in milk). Treatments were [dry matter (DM) basis] as follows: 1) control total mixed ration (TMR, no MN) with no supplemental SBO; 2) MN-treated TMR (22 g of MN/kg of DM) with no supplemental SBO; 3) control TMR including 1.7% SBO; 4) MN-treated TMR including 1.7% SBO; 5) control TMR including 3.4% SBO; and 6) MN-treated TMR including 3.4% SBO. The TMR (% of DM; corn silage, 31.6%; haylage, 21.2%; hay, 4.2%; high-moisture corn, 18.8%; soy hulls, 3.3%; and protein supplement, 20.9%) was offered ad libitum. The experiment consisted of a 2-wk baseline, a 3-wk adaptation, and a 2-wk collection period. Monensin, SBO, and their interaction linearly reduced milk fat percentage. Cows receiving SBO with no added MN (treatments 3 and 5) had 4.5 and 14.2% decreases in milk fat percentage, respectively. Cows receiving SBO with added MN (treatments 4 and 6) had 16.5 and 35.1% decreases in milk fat percentage, respectively. However, the interaction effect of MN and SBO on fat yield was not significant. Monensin reduced milk fat yield by 6.6%. Soybean oil linearly reduced milk fat yield and protein percentage and linearly increased milk yield and milk protein yield. Monensin and SBO reduced 4% fat-corrected milk and had no effect on DM intake. Monensin interacted with SBO to linearly increase milk fat concentration (g/100 g of FA) of total trans-18:1 in milk fat including trans-6 to 8, trans-9, trans-10, trans-11, trans-12 18:1 and the concentration of total conjugated linoleic acid isomers including cis-9, trans-11 18:2; trans-9, cis-11 18:2; and trans-10, cis-12 18:2. Also, the interaction increased milk concentration of polyunsaturated fatty acids. Monensin and SBO linearly reduced, with no significant interaction, milk concentration (g/100 g of FA) of short- and medium-chain fatty acids (

Long-term effects of feeding monensin on milk fatty acid composition in lactating dairy cows.

The objective of this study was to determine the long-term effects of feeding monensin on milk fatty acid (FA) profile in lactating dairy cows. Twenty-four lactating Holstein dairy cows (1.46 +/- 0.17 parity; 620 +/- 5.9 kg of live weight; 92.5 +/- 2.62 d in milk) housed in a tie-stall facility were used in the study. The study was conducted as paired comparisons in a completely randomized block design with repeated measurements in a color-coded, double blind experiment. The cows were paired by parity and days in milk and allocated to 1 of 2 treatments: 1) the regular milking cow total mixed ration (TMR) with a forage-to-concentrate ratio of 60:40 (control TMR; placebo premix) vs. a medicated TMR [monensin TMR; regular TMR + 24 mg of Rumensin Premix per kg of dry matter (DM)] fed ad libitum. The animals were fed and milked twice daily (feeding at 0830 and 1300 h; milking at 0500 and 1500 h). Milk samples were collected before the introduction of treatments and monthly thereafter for 6 mo and analyzed for FA composition. Monensin reduced the percentage of the short-and medium-chain saturated FA 7:0, 9:0, 15:0, and 16:0 in milk fat by 26, 35, 19, and 6%, respectively, compared with the control group. Monensin increased the percentage of the long-chain saturated FA in milk fat by 9%, total monounsaturated FA by 5%, total n-6 polyunsaturated FA (PUFA) by 19%, total n-3 PUFA by 16%, total cis-18:1 by 7%, and total conjugated linoleic acid (CLA) by 43% compared with the control group. Monensin increased the percentage of docosahexaenoic acid (22:6n-3), docosapentaenoic acid (22:5n-3), and cis-9, trans-11 CLA in milk fat by 19, 13, and 43%, respectively, compared with the control. These results suggest that monensin was at least partly effective in inhibiting the biohydrogenation of unsaturated FA in the rumen and consequently increased the percentage of n-6 and n-3 PUFA and CLA in milk, thus enhancing the nutritional properties of milk with regard to human health.

Long-term effects of feeding monensin on methane production in lactating dairy cows.

The objective of this study was to determine the long-term effects of feeding monensin on methane (CH4) production in lactating dairy cows. Twenty-four lactating Holstein dairy cows (1.46 +/- 0.17 parity; 620 +/- 5.9 kg of live weight; 92.5 +/- 2.62 d in milk) housed in a tie-stall facility were used in the study. The study was conducted as paired comparisons in a completely randomized design with repeated measurements in a color-coded, double-blind experiment. The cows were paired by parity and days in milk and allocated to 1 of 2 treatments: 1) the regular milking cow total mixed ration (TMR) with a forage-to-concentrate ratio of 60:40 (control TMR; placebo premix) vs. a medicated TMR (monensin TMR; regular TMR + 24 mg of Rumensin Premix/kg of dry matter) fed ad libitum. The animals were fed and milked twice daily (feeding at 0830 and 1300 h; milking at 0500 and 1500 h) and CH4 production was measured prior to introducing the treatments and monthly thereafter for 6 mo using an open-circuit indirect calorimetry system. Monensin reduced CH4 production by 7% (expressed as grams per day) and by 9% (expressed as grams per kilogram of body weight), which were sustained for 6 mo (mean, 458.7 vs. 428.7 +/- 7.75 g/d and 0.738 vs. 0.675 +/- 0.0141, control vs. monensin, respectively). Monensin reduced milk fat percentage by 9% (3.90 vs. 3.53 +/- 0.098%, control vs. monensin, respectively) and reduced milk protein by 4% (3.37 vs. 3.23 +/- 0.031%, control vs. monensin, respectively). Monensin did not affect the dry matter intake or milk yield of the cows. These results suggest that medicating a 60:40 forage-to-concentrate TMR with 24 mg of Rumensin Premix/kg of dry matter is a viable strategy for reducing CH4 production in lactating Holstein dairy cows.

Effect of monensin delivery method on dry matter intake, body condition score, and metabolic parameters in transition dairy cows.

An investigation was conducted to compare the effects of the monensin controlled-release capsule, monensin sodium in feed, and a negative control on feed intake and metabolic parameters in a randomized and blinded clinical trial. A total of 136 Holstein cows and heifers were assigned to a negative control group, administered a monensin controlled-release capsule (CRC) or administered 22 mg/kg of dry matter of monensin sodium in the total mixed ration (premix). Cows were enrolled 3 wk prior to expected calving; at this time monensin treatment began. Cows were located at the Elora Dairy Research Centre (Elora, Ontario, Canada). Blood samples were obtained at enrollment, at 1 wk prior to expected calving date, at calving, and at 1 and 2 wk postpartum. Sera from these samples were analyzed for beta-hydroxybutyrate (BHBA), nonesterified fatty acids, glucose, urea, bilirubin, aspartate aminotransferase activity, insulin, and cortisol. Cows were assigned a body condition score upon enrollment and upon completion of the trial. The dry matter intake was measured for all cows for the entire experimental period (12.0, 11.7, and 11.3 kg/d for control, premix, and CRC groups, respectively). However, no differences in dry matter intake between treatment groups were noted. The interaction of experimental group and sampling time was significant for serum concentration of BHBA and urea. Both monensin delivery methods significantly decreased serum BHBA postpartum. Urea concentrations were increased in the postpartum period compared with the prepartum samples. The CRC group had a significant impact on reducing the loss in body condition over the study period. Serum concentrations of all measured metabolic parameters varied over the peripartum period. Calving season, parity, and body condition score at the start of the study period influenced many of the measured metabolic parameters.

Effects of prepartum administration of a monensin controlled release capsule on rumen pH, feed intake, and milk production of transition dairy cows.

Effects of prepartum administration of a monensin controlled release capsule (CRC) on rumen pH, dry matter intake, and milk production during the transition period and early lactation were determined in 16 multiparous Holstein cows. Cows were divided into blocks of 2 depending on calving date. Cows were fed either a close-up dry cow or a lactating cow total mixed ration ad libitum. Rumen pH was monitored continuously using indwelling probes. Monensin did not affect average daily rumen pH, time below pH 6, time below pH 5.6, area below pH 6, and area below pH 5.6 throughout the experiment. Average daily pH, time below pH 6, and time below pH 5.6 before calving were 6.62, 65.6 min/d, and 17.6 min/d, respectively, and did not differ among the weeks before calving. Average daily pH, time below pH 6, and time below pH 5.6 were 6.19, 443.3 min/d, and 115.5 min/d, respectively, during the first week after calving, and were 6.36, 204.3 min/d, and 52.4 min/d, respectively, during the sixth week after calving. In the weeks after calving, average daily pH showed a quadratic increase, time below pH 6 showed a quadratic decrease, and time below pH 5.6 showed a linear decrease. Monensin did not affect dry matter intake and daily yields of milk, milk fat, and milk protein. Results suggest that prepartum administration of a monensin CRC did not increase rumen pH in multiparous cows fed the experimental diets during the transition period and early lactation.

Effects of monensin and stage of lactation on variation of blood metabolites within twenty-four hours in dairy cows.

Effects of prepartum administration of a monensin controlled release capsule (CRC) and stage of lactation on variation of blood metabolites within 24 h were determined in 16 dairy cows. Cows were fed a total mixed ration ad libitum twice daily at 0700 and 1300 h. At calving, cows were switched from a close-up dry cow diet to a lactating cow diet. Cows were blood sampled every 3 h for 24 h at 3 stages of lactation, including 1 wk before calving (wk -1), 1 wk after calving (wk 1), and 6 wk after calving (wk 6). Serum concentrations of glucose, beta-hydroxybutyrate (BHBA), nonesterified fatty acids (NEFA), and urea exhibited significant variation within 24 h. Glucose and NEFA were, respectively, 0.09 and 0.08 mM lower between 1030 and 2230 h than between 2230 and 1030 h. beta-Hydroxybutyrate and urea were, respectively, 95.1 and 0.49 mM higher between 1030 and 2230 h than between 2230 and 1030 h. Monensin did not significantly affect glucose, NEFA, and urea in this study. Monensin reduced BHBA at wk 1, but not at wk -1 or wk 6. Glucose was lower and BHBA and NEFA were higher at wk 1 compared with wk -1 and wk 6. Urea was higher at wk 6 compared with wk -1. The variation within 24 h of glucose, BHBA, and NEFA were not affected by monensin and stage of lactation. Diurnal variation of urea was affected by stage of lactation, but not by monensin.

Effects of monensin on ruminal forage degradability and total tract diet digestibility in lactating dairy cows during grain-induced subacute ruminal acidosis.

The effects of monensin premix supplementation on ruminal pH characteristics and forage degradability, and total tract diet digestibility during grain-induced subacute ruminal acidosis (SARA) in lactating dairy cows receiving a total mixed ration were investigated. Six multiparous, rumen-fistulated Holstein cows were used in a 2-treatment, 2-period (5 wk per period) crossover design. During wk 5 (d 29 to 35) of each period, SARA was induced using a grain challenge model, and ruminal pH was measured continuously using indwelling pH probes. Ruminal degradation of corn silage and alfalfa haylage was determined using the in situ (nylon bag) technique, and total tract diet digestibility was determined by total fecal collection during wk 5. Monensin supplementation did not affect dry matter intake, milk yield, and composition, and ruminal pH characteristics under these experimentally induced SARA conditions. Rates of ruminal forage fiber degradability were similar between control and monensin-treated cows; however, monensin supplementation increased total tract fiber digestion. This study indicates that monensin altered total tract nutrient digestion by increasing fiber digestion at postruminal sites.

Comparison of techniques for measurement of rumen pH in lactating dairy cows.

Subacute rumen acidosis is thought to be a common condition in early lactating dairy cattle; however, diagnosis is difficult. There are currently only two techniques available for measuring rumen pH under field conditions: rumenocentesis and oral stomach tube. Sixteen rumen-fistulated cows were sampled in four sites of the rumen (cranial-ventral, caudal-ventral, central, and cranial-dorsal) with a rumen cannula. Rumen pH results were compared to those obtained at the same time with rumenocentesis and with an oro-ruminal (Geishauser) probe. Rumen fluid was obtained between 6 and 12 wk of lactation. Samples were analyzed for pH, lactate, bicarbonate, sodium, potassium, and chloride. Rumen pH results were also compared to those obtained from 24-h continuous rumen pH measurement using indwelling rumen pH probes. Oro-ruminal probe samples had the highest pH values and the highest bicarbonate concentrations. Rumenocentesis samples had the lowest pH values and the lowest bicarbonate concentrations. Small differences in electrolyte concentrations were noted among rumen fluid collection techniques in the different rumen sites. The highest correlations of rumen pH were obtained between rumenocentesis and rumen cannulation (cranial-ventral), and between rumen cannulation (cranial-ventral) and the 24-h indwelling pH meter. Compared with samples obtained from the cranial-ventral rumen, rumenocentesis was more sensitive than the oro-ruminal probe in the measurement of low rumen pH; both techniques were moderately specific. The most accurate field technique was rumenocentesis. Improved field techniques are required for better on-farm diagnosis of subacute rumen acidosis.

Ovarian follicular activity in lactating Holstein cows supplemented with monensin.

The objective of this study was to determine effects of monensin on ovarian follicular development and reproductive performance in postpartum dairy cows. Forty-eight multiparous Holstein cows were randomly assigned to receive either a control total mixed ration (n = 24) or the same diet plus 22 mg of monensin/kg (n = 24) from 21 d before anticipated calving until cows were either confirmed pregnant or were >180 d postpartum. Monensin had no effect on development of the first dominant follicle postpartum or the numbers of class 1 (3 to 5 mm), 2 (6 to 9 mm), or 3 (10 to 15 mm) follicles. Control cows had more class 4 (>15 mm) follicles at 10 to 13 d postpartum than cows in the monensin group. The first dominant follicle postpartum ovulated, regressed, or became cystic unrelated to differences between diets. However, the first ovulation postpartum occurred earlier in monensin-fed cows than in the control group (27.2 +/- 2.1 d vs. 32.4 +/- 1.5 d), with no dietary effects on the diameter of the ovulating follicle. Similarly, treatments did not differ in the proportion of cows with 2 or 3 waves of ovarian follicular development per cycle, nor in the number of follicles of all classes during the breeding period. Times of ovulation following treatment with prostaglandin F2alpha were not different between dietary groups. Pregnancy rates after timed artificial insemination were similar between diets. Supplementation with monensin resulted in a shorter postpartum interval to first ovulation but did not affect other reproductive measures in healthy, lactating dairy cows.

Effect of a monensin controlled release capsule on metabolic parameters in transition dairy cows.

A prospective field study involving 251 Holstein cows and heifers from five dairy farms near Guelph, Ontario, Canada, was conducted to measure the effect of monensin delivered in a controlled release capsule 3 wk precalving on metabolic function in dairy cows immediately pre- and postcalving. At 3 wk before expected calving, cows were randomly assigned to receive either a controlled release capsule containing monensin or to serve as negative controls. Cows were blood sampled once per week precalving and once in the week following calving, at the same time of day and the same day of the week. Serum was evaluated for beta-hydroxybutyrate (BHBA), nonesterified fatty acids (NEFA), cholesterol, urea, glucose, calcium, and phosphorus. Monensin-treated cows had significantly decreased NEFA and BHBA and significantly increased concentrations of serum cholesterol and urea in the week immediately precalving. No effect of treatment was observed for calcium, phosphorus, or glucose in the precalving period. After calving, concentrations of phosphorus were lower and BHBA tended to be lower, and cholesterol and urea were higher in monensin-treated cows. There was no effect of treatment on NEFA, glucose, or calcium in the first week postcalving. Monensin treatment administered precalving significantly improved indicators of energy balance in both the immediate precalving and postcalving periods. The findings indicate better energy metabolism in monensin-treated cows as they approach calving. Improvement of energy balance before calving is important for the prevention of energy associated metabolic diseases, such as retained placenta, clinical ketosis, and displaced abomasum, which might occur immediately postcalving.

Efficacy of intramammary tilmicosin and risk factors for cure of Staphylococcus aureus infection in the dry period.

The objective ofthis study was to evaluate the efficacy of intramammary tilmicosin, administered at drying-off, for eliminating Staphylococcus aureus infection, and to identify risk factors for S. aureus cure during the dry period. A total of 219 naturally infected cows, representing 308 quarters, were randomized to receive either one of two treatments at drying-off. Cows received either an intramammary infusion of 500 mg of benzathine cloxacillin, or a sterile solution containing 1,500 mg of tilmicosin. All cows had quarter milk samples taken aseptically three times before dry-off, and at wk 1, 2, and 4 of the subsequent lactation. Overall, 62% of cows and 67.5% of quarters infected with S. aureus cured during the dry period. The cure following administraton of tilmicosin was 67.3 and 72.5% for cows and quarters, respectively. By comparison, the cure achieved with cloxacillin was 56.9 and 62.9% of cows and quarters. Cows receiving tilmicosin were 2.1 times more likely to cure. The cure rate for cows decreased as the linear score on the last DHI test increased, and as the amount of S. aureus being shed increased. Quarters that cultured positive multiple times before drying-off were less likely to cure. Staphylococcus aureus infections located in front quarters of the udder were 2 times more likely to cure than those in hind quarters. Results of this study demonstrate that intramammary tilmicosin at drying-off is efficacious in curing existing S. aureus during the dry period. Risk factors associated with the cure of S. aureus were identified.

Short communication: Effects of a monensin premix on milk fatty acid content during subacute ruminal acidosis in dairy cows.

The effects of a monensin premix on milk fatty acid content during grain-induced subacute ruminal acidosis (SARA) in Holstein cows receiving a total mixed ration was investigated. Six multiparous, rumen-fistulated Holstein cows were used in a two-treatment, two-period crossover design with 6-wk periods. Experimental treatments were either a monensin premix or a placebo premix. At the beginning of wk 4, SARA was induced in experimental cows for a 10-d period using a grain challenge model. The administration of a monensin premix elevated milk fat proportion of total short-chain saturated fatty acids (sum of C4 to C15). Milk fat proportions of conjugated linoleic acid isomers were unaffected. Linolenic acid (C18:3n3) proportion in milk fat of monensin-treated cows were lower when compared with placebo-treated cows during the SARA period. Results from this study indicate that dietary supplementation with monensin during SARA had little effect on milk fatty acid content.

A field study of dietary interactions with monensin on milk fat percentage in lactating dairy cattle.

Ninety-one Ontario Holstein dairy herds were surveyed about their lactating cow ration and use of a premix containing monensin to identify possible dietary interactions with monensin on milk fat suppression. All herds were enrolled in Ontario Dairy Herd Improvement (DHI) milk recording, and results from four DHI tests were used. Herd mean fat tests were calculated only for cows between 100 and 200 d in milk to avoid potential confounding due to stage of lactation. Wet forage and total mixed ration (TMR) samples from all herds were evaluated for particle size using the Penn State Particle Size Separator. Of the herds using monensin (n = 58), the dose (per kg of dry matter) ranged from 9 to 14 mg/kg in TMR-fed herds and from approximately 9 to 23 mg/kg in herds in which concentrates were fed separately from forages (component-fed). Of the samples submitted for particle size evaluation, 15% of the haylage (n = 80), 14% of the corn silage (n = 79), and 42% of the TMR (n = 58) samples were classified as having low fiber. There was a significant negative univariable association between monensin and mean milk fat percentage. Monensin significantly reduced milk fat percentage in TMR-fed but not component-fed herds. Fiber length significantly interacted with monensin in TMR-fed herds: Herds that had low fiber in their TMR (< or = 6.0% in the top screen) were susceptible to milk fat decrease by monensin, whereas herds that had adequate fiber (> 6.0%) were not. Monensin also significantly reduced milk fat percentage in herds receiving diets low in nonstructural carbohydrate (< 40.2%) but not in those receiving diets high in NSC (> or = 40.2%). The results of this study suggest that there are significant interactions between monensin and certain dietary factors on milk fat suppression in Holstein dairy herds.

Prepartum monensin for the reduction of energy associated disease in postpartum dairy cows.

A total of 1317 Holstein cows from 45 farms in the Canadian provinces of Quebec, Prince Edward Island (PEI) and Ontario were enrolled in a randomized trial during 1998 and 1999 to further confirm the efficacy of a monensin controlled release capsule in preventing periparturient disease in lactating dairy cows. Cows were randomized on the farms to receive either a monensin controlled release capsule (CRC) 2 to 4 wk before expected calving or to serve as negative controls. Health data were collected for 90 d postcalving and were analyzed with logistic regression accounting for the intraherd correlation with generalized estimating equations. Monensin CRC significantly reduced the incidence of both clinical ketosis and abomasal displacement post-calving. There was a numerical but nonsignificant decrease in the incidence of retained placenta in cows receiving a monensin CRC. A pooled analysis of two separate but similar studies (conducted in 1995 and 1998) demonstrated a strengthened association between monensin CRC administration precalving and reduced periparturient disease. A 40% reduction in both abomasal displacement and clinical ketosis was observed with precalving administration of a monensin CRC. In addition, the larger dataset highlighted a trend for a 25% reduction in the incidence of retained placenta in monensin-treated cows. Improved energy metabolism as a result of monensin treatment is likely the mechanism for the reduction in incidence of all three of these diseases. Thus the term "energy associated disease" was created to assess the combined impact of the precalving monensin treatment on the incidence of retained placenta, displaced abomasum, and clinical ketosis. The monensin controlled release capsule reduced the incidence of energy associated disease by 30%.

The efficacy of intramammary tilmicosin at drying-off, and other risk factors for the prevention of new intramammary infections during the dry period.

The objective of this study was to compare the efficacy of an intramammary infusion, containing tilmicosin phosphate, to an infusion of a negative control intramammary placebo for preventing new intramammary infections (IMI) during the dry period. Cows were enrolled from 24 dairy herds from three geographical regions of Canada. Data from 248 cows and 938 bacteriologically negative quarters at drying-off are summarized. Overall, the rate of new IMI during the dry period was 16.7% of quarters. The new infection rates for quarters that received intramammary tilmicosin compared with the intramammary placebo were 14.4 and 19.4%, respectively. The majority of new IMI was caused by coagulase-negative staphylococci (49%) and environmental streptococcal organisms (26.8%). The probability for quarters to develop new IMI in the dry period was significantly increased when cows had higher milk production before drying-off (P = 0.04), when cows had longer dry periods (P = 0.02), and when dry cows were housed in tie-stall barns (P = 0.002). Higher parity cows and those that had a linear score somatic cell count (SCC) above 4 on the last DHI test were also at increased risk for new IMI (P < 0.10). Administration of intramammary tilmicosin appears to be an efficacious therapy for prevention of new IMI; however, there is currently no approved intramammary formulation of this product available. Use of blanket dry cow antibiotic therapy compared to selective dry cow therapy, as well as the importance of identifying risk factors and managing the environment of dry cows are discussed.

Effects of a monensin controlled-release capsule or premix on attenuation of subacute ruminal acidosis in dairy cows.

The effects of monensin, administered either as a controlled release capsule (CRC) or a premix, on attenuating grain-induced subacute ruminal acidosis (SARA) and on ruminal fermentation characteristics in Holstein cows receiving a total mixed ration were investigated in two experiments. In both experiments, six multiparous, rumen-fistulated Holstein cows were used in a two-treatment, two-period crossover design with 6-wk periods. In Experiment 1, treatments were either a monensin CRC or a placebo CRC. In Experiment 2, treatments were either a monensin premix or a placebo premix. In both experiments, at the beginning of wk 4 SARA was induced in experimental cows for a 10-d period with a grain challenge model, and ruminal pH was measured continuously using indwelling pH probes. The administration of monensin either as a CRC or a premix had no effect on ruminal pH characteristics. Neither monensin CRC nor premix had an effect on ruminal volatile fatty acid concentrations, but reduced the acetate:propionate ratio. Monensin premix-treated cows were observed to have increased milk yield, largely as a result of a higher dry matter intake in monensin-treated cows compared to control cows. Milk fat content and yield were lower in monensin-treated cows compared to placebo-treated cows during SARA. In conclusion, there is no evidence that monensin was efficacious in raising ruminal pH during SARA under the conditions employed in this study.

Efficacy of narasin in the prevention of necrotic enteritis in broiler chickens.

The efficacy of narasin in the control of necrotic enteritis (NE) was investigated in a floor pen study of 2000 broiler chickens using a Clostridium perfringens feed inoculum challenge model. Treatments were 1) nonmedicated, nonchallenged; 2) nonmedicated, challenged; 3) narasin, nonchallenged; 4) narasin, challenged. Narasin was administered at 70 ppm in the feed from day 0 to trial termination on day 41. Challenge inoculum contained approximately 1 x 10(8) colony-forming units CP/ml and was administered from day 14 to day 16. In the unmedicated groups, challenged birds had significantly (P < 0.05) lower mean body weight and reduced feed efficiency at day 21 and significantly (P < 0.01) higher cumulative NE mortality at day 41 compared with unchallenged. Similarly, among unmedicated birds, those challenged had a significantly (P < 0.01) higher mean NE score on day 17 and significantly (P < 0.05) higher mean huddling scores on days 15-17 than unchallenged. Among challenged birds, those fed narasin had significantly (P < 0.05) higher mean body weight and improved feed efficiency at days 21 and 41 and significantly (P < 0.01) lower cumulative NE mortality at day 41 than unmedicated. Similarly, among challenged birds, those receiving narasin had a lower mean NE score on day 17 (P > 0.05) and significantly (P < 0.05) lower huddling scores on days 16 and 17 than unmedicated. Coccidiosis lesion scores were zero for birds euthanatized from all treatment groups on day 17, suggesting that the beneficial effects of narasin were not due to prevention of coccidiosis. This study thus provides evidence that narasin is effective in the prevention of necrotic enteritis in broiler chickens.

Use of ionophores in lactating dairy cattle: a review.

Ionophores are feed additives that alter rumen microbial populations through ion transfer across cell membranes. Although ionophores have been used widely in the beef industry for improved feed efficiency and control of coccidiosis, there has been limited use by the dairy industry. In Canada, the label warning prohibiting the use of monensin premix in lactating dairy cattle was removed in June 1996. Following this, in December 1997, a controlled release capsule containing monensin was approved for use in dairy cattle as an aid to prevent subclinical ketosis. Monensin may have several advantages for dairy cattle, including improved energy metabolism, increased milk production, and altered milk components. This literature review was primarily conducted in 1996 by using the Agricola and CAB search databases. Other relevant articles published since the search (up to 1998) have been added. This review will provide practitioners with relevant references in the published literature regarding ionophore use in dairy cattle. It should also give some guidance as to what effects might be anticipated with the use of ionophores in lactating dairy animals.